GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Defence Therapeutics Inc (XCNQ:DTC) » Definitions » PensionAndRetirementBenefit

Defence Therapeutics (XCNQ:DTC) PensionAndRetirementBenefit : C$0.00 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Defence Therapeutics PensionAndRetirementBenefit?

Defence Therapeutics's PensionAndRetirementBenefit for the quarter that ended in Dec. 2023 was C$0.00 Mil.


Defence Therapeutics PensionAndRetirementBenefit Historical Data

The historical data trend for Defence Therapeutics's PensionAndRetirementBenefit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Defence Therapeutics PensionAndRetirementBenefit Chart

Defence Therapeutics Annual Data
Trend Jun20 Jun21 Jun22
PensionAndRetirementBenefit
- - -

Defence Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23
PensionAndRetirementBenefit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Defence Therapeutics PensionAndRetirementBenefit Calculation

PensionAndRetirementBenefit is the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement.


Defence Therapeutics (XCNQ:DTC) Business Description

Traded in Other Exchanges
Address
200 Burrard Street, Suite 1680, Vancouver, BC, CAN, V6C3L6
Defence Therapeutics Inc is engaged in the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The Company has one operating segment, being research and development.
Executives
Sarkis Meterissian Director